David König

Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours

Ignacio Melero, Maria de Miguel Luken, Guillermo de Velasco et al. · Nature · 2024 · 93 citations · Full text

Life Sciences, Immunology, Oncology +17

Siglec Receptors Modulate Dendritic Cell Activation and Antigen Presentation to T Cells in Cancer

Jinyu Wang, Michela Manni, Anne Bärenwaldt et al. · Frontiers in Cell and Developmental Biology · 2022 · 52 citations · Full text

Medicine, Immunology, Oncology +17

Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials

David König, Sämi Schär, Diem Vuong et al. · ESMO Open · 2022 · 24 citations · Full text

Medicine, Oncology, Surgery +16

Small cell transformation in EGFR-mutated non-small cell lung cancer: DLL3 expression and efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with chemotherapy

Felix Carl Saalfeld, Petros Christopoulos, Carina Wenzel et al. · European Journal of Cancer · 2024 · 23 citations · Full text

Medicine, Oncology, Pharmacology +17

Binimetinib, pemetrexed and cisplatin, followed by maintenance of binimetinib and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations. The phase 1B SAKK 19/16 trial

Patrizia Froesch, Michael Mark, Sacha I. Rothschild et al. · Lung Cancer · 2021 · 21 citations

Medicine, Oncology, Pharmacology +12